

## Publikationen

Behe M., Alt K., Deininger F., Bühler P., Wetterauer U., Weber W. A., Elsässer-Beile U., Wolf P. In Vivo Testing of <sup>177</sup>Lu-Labelled Anti-PSMA Antibody as a New Radioimmunotherapeutic Agent Against Prostate Cancer. *In Vivo*. Jan.-Feb. 25(1):55-9 (2011).

Wolf P., Alt K., Wetterauer D., Bühler P., Gierschner D., Katzenwadel A., Wetterauer U., Elsässer-Beile U. Preclinical evaluation of a recombinant anti-PSMA single-chain immunotoxin against prostate cancer. *J Immunother*, 33:262–271 (2010).

Bühler P., Wetterauer D., Gierschner D., Wetterauer U., Elsässer-Beile U. and Wolf P. Influence of Structural Variations on Biological Activity of anti-PSMA scFv and Immunotoxins Targeting Prostate Cancer. *Anticancer Res*, Apr. 30:3373-3379 (2010).

Fortmüller K., Alt K., Wolf P., Gierschner D., Baum V., Freudenberg N., Elsässer-Beile U., Bühler P. Effective Targeting of Prostate Cancer by Lymphocytes Redirected by a PSMAxCD3 Bispecific Single-Chain Diabody. *Prostate*, 2010 Oct 13. [Epub ahead of print].

Wolf P., Freudenberg N., Bühler P., Alt K., Schultze-Seemann W., Wetterauer U., Elsässer-Beile U. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. *Prostate*, Apr 1;70(5):562-9 (2010).

Alt K., Wiehr S., Ehrlichmann W., Reischl G., Wolf P., Pichler B. J., Elsässer-Beile U., Bühler P. High-resolution Animal PET Imaging of Prostate Cancer Xenografts With Three Different <sup>64</sup>Cu-Labeled Antibodies Against Native Cell adherent PSMA. *Prostate*, Sep15; 70(13):1413-1421 (2010).

Bühler P., Wolf P., Katzenwadel A., Schultze-Seemann W., Wetterauer U., Freudenberg N., Elsässer-Beile U. Primary prostate cancer cultures are models for androgen-independent transit amplifying cells. *Oncol Rep*, Feb;23(2):465-70 (2010).

Bühler P., Fischer T., Wolf P., Gierschner D., Schultze-Seemann W., Wetterauer U. and Elsässer-Beile U. Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors. *Urol Int* , 84:203–211 (2010).

Wolf P., Elsässer-Beile U. Pseudomonas Exotoxin A: from virulence factor to anti-cancer agent. *Int J Med Microbiol*, 299(3): 161-176 (2009).

Elsässer-Beile U., Bühler P., Wolf P. Targeted Therapies for Prostate Cancer against the Prostate Specific Membrane Antigen. *Current Drug Targets*, Feb;10(2):118-25 (2009).

Wolf P., Elsässer-Beile U. Pseudomonas Exotoxin A based immunotoxins for targeted cancer therapy. In *Emerging Cancer Therapies, Microbial Approaches and Biotechnological Tools*. John Wiley and Sons, Inc. 2010, ISBN: 978-0-470-44467-2.

Bühler P., Molnar E., Dopfer E. P., Wolf P., Gierschner D., Wetterauer U., Schamel W. W. A., Elsässer-Beile U. Target-dependent T Cell Activation by Co-Ligation with a PSMAxCD3 Diabody Induces Lysis of Prostate Cancer Cells. *J of Immunother*, 32: 565-573 (2009).

Liu J., Kopečková P., Bühler P., Wolf P., Pan H., Bauer H., Elsässer-Beile U., Kopeček J. Biorecognition and Subcellular Trafficking of HPMA Copolymer – Anti PSMA Antibody Conjugates by Prostate Cancer Cells. *Mol Pharm*, Jun-Jul;6(3):959-70 (2009).

Elsässer-Beile U., Reischl G., Wiehr S., Bühler P., Wolf P., Alt K., Ca F., Shively J., Machulla H.-J., Pichler B. J. PET Imaging of Prostate Cancer Xenografts with a highly specific antibody against the prostate specific membrane antigen. *J Nucl Med*, 50(4): 606-611 (2009).

Bühler P., Wolf P., Elsässer-Beile U. Targeting the prostate specific membrane antigen for prostate cancer therapy. *Immunotherapy*, 1(3): 471-481 (2009).

Wolf, P., Alt, K., Bühler, P., Katzenwadel, A., Wetterauer, U., Tacke, M., Elsässer-Beile, U. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. *Prostate* 68(2), 129-138 (2008).

Bühler, P., Wolf, P., Gierschner, D., Schaber, I., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Tacke, M., Swamy, M., Schamel, W.W.A., Elsässer-Beile, U. A bispecific diabody directed against prostate specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. *Cancer Immunol. Immunother*, 57(1), 43-52 (2008).

Bühler, P., Wolf, P., Reischl, G., Pichler, B., Shively, J., Alt, K., Wetterauer, U., Elsässer-Beile, U. PET Imaging of prostate cancer with a highly specific anti-PSMA antibody. *Tumor Biol* 28 (Suppl 1) p. 90 (2007).

Wolf, P., Alt, K., Bühler, P., Wetterauer, U., Elsässer-Beile, U. Selective Suppression of human prostate tumor growth in mice by a recombinant anti-PSMA immunotoxin. *Tumor Biol* 28 (Suppl 1) p. 68 (2007).

Elsässer-Beile, U., Wolf, P., Gierschner, D., Bühler, P., Schultze-Seemann, W., Wetterauer, U. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. *The Prostate* 66 (13), 1359-1370, (2006).

Wolf, P., Gierschner, D., Bühler, P., Wetterauer, U., Elsässer-Beile, U. A recombinant PSMA-specific single-chain immunotoxin (A5-PE40) has potent and selective toxicity against prostate cancer cells. *Cancer Immunol Immunother*, 55 (11), 1367-1373 (2006).

Bühler, P., Leiber, C., Lucht, M, Wolf P., Wetterauer, U. , Elsässer-Beile, U. Intravesical mistletoe extract for adjuvant treatment of superficial urinary bladder cancer. *PharmacologyOnLine*, 3, 442-448 (2006).

Elsässer-Beile, U., Rostock, M., Bühler, P., Wetterauer, U., Schumacher, M., Bartsch, H. Immunological effects of Echinacea purpurea extract in patients with breast cancer. *PharmacologyOnLine*, 3, 474-481(2006).

Elsässer-Beile, U., Leiber, C., Bühler, P., Mengs, U., Wetterauer, U. Adjuvant intravesical treatment of superficial urinary bladder cancer with Mistletoe extract. *Tumor Biol* 27 (Suppl 1), p. 25 (2006).

Bühler, P., Elsässer, U., Freudenberg, N., Wetterauer, U. Primary tumor cultures as model for androgen depletion of prostate cancer. *Tumor Biol* 27 (Suppl 1) p. 56 (2006).

Bühler, P., Freudenberg, N., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Elsässer-Beile, U. Hormonal ablation in primary prostate cancer cultures – Effects on cell growth and gene expression. *Tumor Biol* 27(Suppl 2) p. 36 (2006).

Wolf, P., Bühler, P., Gierschner, D., Wetterauer, U., Elsässer-Beile, U. A recombinant PSMA-specific single-chain immunotoxin as therapeutical option for prostate cancer. *Tumor Biol* 27(Suppl 2) p. 97 (2006).

Elsässer-Beile, U., Bühler, P., Wolf, P., Katzenwadel, A., Wetterauer, U. T-Cell mediated lysis of prostate cancer cells with a single-chain PSMA/CD3 bispecific antibody. *Tumor Biol* 27(Suppl 2) p. 36 (2006).

Elsässer-Beile, U., Leiber, C., Wolf, P., Lucht, M., Mengs, U., Wetterauer, U. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. *J. Urol* 174, 76-79, (2005).

Elsässer-Beile, U., Leiber, C., Wetterauer, U., Bühler, P., Wolf, P., Lucht, M., Mengs, U. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer. *Anticancer Res.* 25, 4733-4736, (2005).

## Preise

09/2010

Karen Alt ISOBM (International Society of Oncology and Biomarkers) Merit Award

09/2010	Kerstin Fortmüller ISOBM (International Society of Oncology and Biomarkers) Merit Award
09/2007	Patrick Bühler EGTM (European Group on Tumor Markers) Young Investigator Award
06/2007	Dr. Philipp Wolf Eleonore und Fritz Hodeige-Preis 2007 für innovative, erfolgreiche medizinische Therapien entwickelt an der Universitätsklinik der Albert-Ludwigs-Universität Freiburg